Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma / 医学前沿
Frontiers of Medicine
; (4): 811-815, 2020.
Article
in En
| WPRIM
| ID: wpr-880944
Responsible library:
WPRO
ABSTRACT
Mantle cell lymphoma (MCL) is a distinct histological type of B-cell lymphoma with a poor prognosis. Several agents, such as proteasome inhibitors, immunomodulatory drugs, and inhibitors of B cell lymphoma-2 and Bruton's tyrosine kinase have shown efficacy for relapsed or refractory (r/r) MCL but often have short-term responses. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin's lymphoma. However, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especially in MCL. In this report, we described a 70-year-old patient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cell therapy. CAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient. This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL, who are generally elderly and have comorbid conditions.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Immunotherapy, Adoptive
/
Lymphoma, Mantle-Cell
/
Cell- and Tissue-Based Therapy
/
Receptors, Chimeric Antigen
/
Neoplasm Recurrence, Local
Limits:
Adult
/
Aged
/
Humans
Language:
En
Journal:
Frontiers of Medicine
Year:
2020
Document type:
Article